Program
galvokimig
Also written as “Galvokimig” and “UCB9741”.
Its studies are mostly in Dermatitis, Atopic · Bronchiectasis · Bronchitis, Chronic, led by UCB.
Furthest: phase 2, since Nov 19, 20205 company-led studies, 3 open or runningNext primary completion: May 17, 2027 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| UCB | 53 open or running | phase 2since Nov 19, 2020 | Nov 19, 2020 | May 17, 2027phase 2 · NCT07277660 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Nov 19, 2020First study: phase 2 study in Dermatitis, AtopicFirst studyNCT04643457 · 107 enrolled · Bulgaria, Germany, Netherlands and more
- Mar 11, 2024Phase 1 study in Healthy ParticipantsNCT06315335 · 40 enrolled · United States
- Dec 2, 2025Phase 2 study in Dermatitis, AtopicNCT07277660 · 165 enrolled · United States, Bulgaria, Canada and more
- Jul 17, 20262 phase 2 studiesNCT07720375, NCT07725939
Ahead
- May 17, 2027Primary completion: phase 2 study in Dermatitis, AtopicNCT07277660
- Feb 28, 2029Primary completion: phase 2 study in Non-cystic Fibrosis BronchiectasisNCT07720375
- Jun 29, 2029Primary completion: phase 2 study in Pulmonary Disease, Chronic ObstructiveNCT07725939
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 5 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07725939Pulmonary Disease, Chronic Obstructive · United States, China | 2 | Recruiting | Jun 29, 2029 | 402 |
| NCT07720375Non-cystic Fibrosis Bronchiectasis · United States | 2 | Recruiting | Feb 28, 2029 | 300 |
| NCT07277660Dermatitis, Atopic · United States, Bulgaria, Canada and more | 2 | Active, not recruiting | May 17, 2027 | 165 |
| NCT06315335Healthy Participants · United States | 1 | Completed | Jan 1, 2025 | 40 |
| NCT04643457Dermatitis, Atopic · Bulgaria, Germany, Netherlands and more | 2 | Completed | Apr 23, 2024 | 107 |
How it is read
Names in the registry
- “Galvokimig”, 3 entries
- “UCB9741”, 2 entries
Conditions, from the studies’ own filings
- Dermatitis, Atopic, 2 studies
- Bronchiectasis, 1 study
- Bronchitis, Chronic, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.